Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC
Status:
Recruiting
Trial end date:
2025-12-20
Target enrollment:
Participant gender:
Summary
Background: Ablation is important radical treatment in hepatocellular carcinoma (HCC).
However, the 5-year recurrence rate of HCC after ablation is up to 80%. Early and late
recurrences are more likely related to tumor size, tumor multiplicity, vascular invasion,
higher serum AFP level and disease etiology, etc. Some studies suggested that adjuvant
immunotherapy might be associated with decreased recurrence and prolonged RFS. Adjuvant
atezolizumab + bevacizumab (IMbrave 050) showed RFS improvement following curative resection
or ablation. Currently, there is limited study on immunotherapy combined with TKI as
postoperative adjuvant therapy for HCC. This is an open-label, prospective cohort study to
compare the efficacy and safety of tislelizumab plus tyrosine kinase inhibitor (TKI) as
adjuvant therapy versus active surveillance in HCC patients with high risk of recurrence
after curative ablation.